Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents

• Published in: Diabetes care Vol. 38; no. 12; pp. 2274 - 2281
• Main Authors: Rosenstock, Julio, Franco, Denise, Korpachev, Vadym, Shumel, Brad, Ma, Yuhui, Baughman, Robert, Amin, Nikhil, McGill, Janet B.
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01.12.2015
• Subjects: Administration, Inhalation; Adult; Aged; Clinical trials; Diabetes; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin A - analysis; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - therapeutic use; Insulin; Insulin, Regular, Human - administration & dosage; Insulin, Regular, Human - therapeutic use; Male; Metformin - therapeutic use; Microspheres; Middle Aged; Placebo effect; Placebos - administration & dosage; Powders - administration & dosage; Prescription drugs; Treatment Outcome

To investigate the efficacy and safety of prandial Technosphere inhaled insulin (TI), an inhaled insulin with a distinct time action profile, in insulin-naïve type 2 diabetes (T2D) inadequately controlled on oral antidiabetes agents (OADs). Subjects with T2D with HbA1c levels ≥7.5% (58.5 mmol/mol) a...